METRELEPTIN ( DrugBank: Metreleptin )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
265脂肪萎縮症12

265. 脂肪萎縮症


臨床試験数 : 116 薬物数 : 170 - (DrugBank : 61) / 標的遺伝子数 : 26 - 標的パスウェイ数 : 97
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05164341
(ClinicalTrials.gov)
December 202111/11/2021A 12-Month Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Patients With Partial LipodystrophyA 12-Month Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Patients With Partial LipodystrophyPartial LipodystrophyDrug: metreleptin;Drug: PlaceboAmryt PharmaNULLNot yet recruiting5 YearsN/AAll80Phase 3NULL
2NCT04026178
(ClinicalTrials.gov)
November 14, 201830/10/2018Immunogenicity of Metreleptin in Patients With Generalized LipodystrophyA 36-Month, Multicenter, Open Label Phase 4 Study to Evaluate the Immunogenicity of Daily SC Metreleptin Treatment in Patients With Generalized LipodystrophyGeneralized LipodystrophyDrug: MetreleptinAegerion Pharmaceuticals, Inc.NULLRecruiting1 YearN/AAll10Phase 4United States
3EUCTR2017-003014-22-AT
(EUCTR)
25/06/201829/05/2018Leptin in hepatic lipid metabolism in humansThe role of leptin in regulating hepatic lipid metabolism in humans - Leptin and hepatic lipid metabolism lipodystrophy patients, patients after liver transplantation and healthy controls;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]Trade Name: Myalept
Product Name: Myalept
INN or Proposed INN: metrelpetin
Other descriptive name: METRELEPTIN
Medical University of ViennaNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
43Phase 2Austria
4NCT02654977
(ClinicalTrials.gov)
September 29, 201520/1/2015CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial LipodystrophyCLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Recombinant Human Leptin (METRELEPTIN) in Various Forms of Partial LipodystrophyFamilial Partial Lipodystrophy;Nonalcoholic Steatohepatitis;NAFLDDrug: MetreleptinUniversity of MichiganNULLCompleted5 YearsN/AAll11Phase 2United States
5NCT02262806
(ClinicalTrials.gov)
October 14, 20149/10/2014Compassionate Use of Metreleptin in Previously Treated People With Partial LipodystrophyCompassionate Use of Metreleptin in Previously-Treated Patients With Partial LipodystrophyDiabetes;Lipodystrophy;HyperlipidemiaDrug: MetreleptinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NULLActive, not recruiting6 MonthsN/AAll30Phase 2United States
6NCT02262832
(ClinicalTrials.gov)
October 9, 201410/10/2014Compassionate Use of Metreleptin in Previously Treated People With Generalized LipodystrophyCompassionate Use of Metreleptin in Previously-Treated Patients With Generalized LipodystrophyLipodystrophy;Diabetes;HyperlipidemiaDrug: MetreleptinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NULLRecruiting6 MonthsN/AAll30Phase 3United States
7NCT01778556
(ClinicalTrials.gov)
January 26, 201326/1/2013Short-term Effects of Leptin in People With LipodystrophyShort Term Effects of Leptin Withdrawal or Initiation in Lipodystrophy Independent of Energy IntakeLipodystrophyBiological: MetreleptinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NULLCompleted14 Years70 YearsAll25Phase 2United States
8NCT01679197
(ClinicalTrials.gov)
October 8, 201231/8/2012Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With LipodystrophyClinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With LipodystrophyFatty Liver Disease, Nonalcoholic;Nonalcoholic Steatohepatitis;LipodystrophyDrug: MetreleptinUniversity of MichiganNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed5 YearsN/AAll23Phase 2United States
9NCT02404896
(ClinicalTrials.gov)
October 201120/1/2015Expanded Access Metreleptin StudyExpanded-Access for the Use of Metreleptin in Patients With Partial Lipodystrophy Associated With Diabetes Mellitus or HypertriglyceridemiaFamilial Partial LipodystrophyDrug: MetreleptinUniversity of MichiganNULLNo longer available18 YearsN/AAllUnited States
10NCT00677313
(ClinicalTrials.gov)
November 200812/5/2008An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With LipodystrophyAn Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With LipodystrophyLipodystrophyDrug: metreleptinBristol-Myers SquibbNULLActive, not recruiting5 YearsN/ABoth41N/AUnited States
11NCT01511016
(ClinicalTrials.gov)
February 200311/1/2012Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy SyndromeThe Effect of Leptin Therapy on Abnormal Lipid Kinetics in Subjects With HIV Lipodystrophy SyndromeHIV LipodystrophyDrug: Human recombinant leptin (metreleptin);Drug: PlaceboBaylor College of MedicineNULLCompleted18 Years64 YearsMale17N/AUnited States
12NCT00025883
(ClinicalTrials.gov)
October 200127/10/2001Leptin to Treat LipodystrophyLong-Term Efficacy of Leptin Replacement in Treatment of LipodystrophyLipodystrophyDrug: MetreleptinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NULLCompleted6 MonthsN/AAll103Phase 2United States